Browse: Departments   Dates   Agencies  

DOCUMENT ID: [60 Day-08-08AR]

NOTICE: NOTICES

SUBJECT CATEGORY: Proposed Data Collections Submitted for Public Comment and Recommendations

DOCUMENT SUMMARY:

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on [[Page 12450]]
proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046395960 or send comments to Maryam Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MSD74, Atlanta, GA 30333 or send an email to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project

CDC Cervical Cancer StudyNewNational Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is the only organized national screening program in the United States that offers breast and cervical cancer screening to underserved women. Given resource limitations, the screening policies for cervical cancer in the program include an annual Pap test until a woman has had three consecutive normal Pap tests, at which time the Pap test frequency is reduced to every three years. Human papillomavirus (HPV) DNA testing has been approved in the U.S. as a secondary screening tool for Atypical Squamous Cells of Undetermined Significance (ASCUS), and as a primary screening tool for women 30 years of age and older, but it is not currently a reimbursable expense under NBCCEDP guidelines. Adopting HPV DNA testing along with Pap testing in women over 30 could help the program better utilize resources by extending the screening interval of women who are cytology negative and HPV test negative, which is estimated to be 8090% of women.

In 2005, the NBCCEDP convened an expert panel to evaluate policies on reimbursement of the HPV DNA test as an adjunct to the Pap test for primary screening. The panel recommended that the program not reimburse for the HPV DNA test but instead requested that pilot studies be performed to measure the feasibility, acceptability and barriers to use of the test.

In response to the expert panel's recommendations, CDC proposes to conduct a pilot study at 18 clinics in the state of Illinois. The proposed study will examine whether or not there is an increase in the cervical cancer screening interval to three years for women in the target age range with a normal Pap test and a negative HPV DNA test. Primary goals of the study are to: (1) Assess whether provider and patient education will lead to extended screening intervals for women who have negative screening results; (2) identify facilitators and barriers to acceptance and appropriate use of the HPV test and longer screening intervals; (3) track costs associated with HPV testing and educational interventions; and (4) identify the HPV genotypes among this sample of low income women. Secondary goals of the study are to: (1) Assess followup of women with positive test results and (2) determine provider knowledge and acceptability of the HPV vaccine.

Approximately 8,000 women between the ages of 35 and 60 who are visiting one of 18 participating clinics for routine cervical cancer screening will be recruited for the study. Approximately 10,000 women must be screened in order to identify 8,000 who are both eligible and willing to be enrolled in the study. The study design calls for data collection over a fiveyear period. Information will be collected primarily from a total of 70 clinical care providers, 18 clinic coordinators, and a sample of 2,600 patients.

CDC plans to request OMB approval for data collection activities to be conducted during the first three years (Phase I) of the fiveyear project. The results of this study will provide information about knowledge, attitudes, beliefs, and cervical cancer screening practices involving lowincome, underserved women, who represent the demographic most needy of highly sensitive screening methodologies that can increase the likelihood of detecting cervical dysplasia at less frequent screening intervals. The findings from this study will help inform policy regarding the HPV DNA test on a national level for cervical cancer screening in the NBCCEDP.

There are no costs to respondents other than their time. Estimated Annualized Burden Hours Number of Average burden Type of respondents Form name Number of responses per per response (in Total burden (in respondents respondent hr) hr) Health Care Providers....................... Baseline Survey for Providers. 23 1 30/60 12 Followup Survey for Providers 23 2 30/60 23 Patients.................................... Screening Script for Patients. 3,333 1 5/60 278 Enrollment Form............... 2,667 1 5/60 222 Baseline Survey for Patients.. 867 1 15/60 217 Followup Survey for Patients. 624 1 10/60 104 Clinic Coordinators......................... Baseline Survey for Clinic 6 1 2 12 Coordinators. Followup Survey for Clinic 6 11 1 66 Coordinators.

Total................................... .............................. ................. ................. ................. 934 [[Page 12451]]

Dated: February 28, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E84492 Filed 3608; 8:45 am]
BILLING CODE 416318P

SUMMARY: Agency Information Collection Activities; Proposals, Submissions, and Approvals,

DOCUMENT BODY 2:

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on [[Page 12450]]
proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046395960 or send comments to Maryam Daneshvar, CDC Acting Reports Clearance Officer, 1600 Clifton Road, MSD74, Atlanta, GA 30333 or send an email to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project

CDC Cervical Cancer StudyNewNational Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) is the only organized national screening program in the United States that offers breast and cervical cancer screening to underserved women. Given resource limitations, the screening policies for cervical cancer in the program include an annual Pap test until a woman has had three consecutive normal Pap tests, at which time the Pap test frequency is reduced to every three years. Human papillomavirus (HPV) DNA testing has been approved in the U.S. as a secondary screening tool for Atypical Squamous Cells of Undetermined Significance (ASCUS), and as a primary screening tool for women 30 years of age and older, but it is not currently a reimbursable expense under NBCCEDP guidelines. Adopting HPV DNA testing along with Pap testing in women over 30 could help the program better utilize resources by extending the screening interval of women who are cytology negative and HPV test negative, which is estimated to be 8090% of women.

In 2005, the NBCCEDP convened an expert panel to evaluate policies on reimbursement of the HPV DNA test as an adjunct to the Pap test for primary screening. The panel recommended that the program not reimburse for the HPV DNA test but instead requested that pilot studies be performed to measure the feasibility, acceptability and barriers to use of the test.

In response to the expert panel's recommendations, CDC proposes to conduct a pilot study at 18 clinics in the state of Illinois. The proposed study will examine whether or not there is an increase in the cervical cancer screening interval to three years for women in the target age range with a normal Pap test and a negative HPV DNA test. Primary goals of the study are to: (1) Assess whether provider and patient education will lead to extended screening intervals for women who have negative screening results; (2) identify facilitators and barriers to acceptance and appropriate use of the HPV test and longer screening intervals; (3) track costs associated with HPV testing and educational interventions; and (4) identify the HPV genotypes among this sample of low income women. Secondary goals of the study are to: (1) Assess followup of women with positive test results and (2) determine provider knowledge and acceptability of the HPV vaccine.

Approximately 8,000 women between the ages of 35 and 60 who are visiting one of 18 participating clinics for routine cervical cancer screening will be recruited for the study. Approximately 10,000 women must be screened in order to identify 8,000 who are both eligible and willing to be enrolled in the study. The study design calls for data collection over a fiveyear period. Information will be collected primarily from a total of 70 clinical care providers, 18 clinic coordinators, and a sample of 2,600 patients.

CDC plans to request OMB approval for data collection activities to be conducted during the first three years (Phase I) of the fiveyear project. The results of this study will provide information about knowledge, attitudes, beliefs, and cervical cancer screening practices involving lowincome, underserved women, who represent the demographic most needy of highly sensitive screening methodologies that can increase the likelihood of detecting cervical dysplasia at less frequent screening intervals. The findings from this study will help inform policy regarding the HPV DNA test on a national level for cervical cancer screening in the NBCCEDP.

There are no costs to respondents other than their time. Estimated Annualized Burden Hours Number of Average burden Type of respondents Form name Number of responses per per response (in Total burden (in respondents respondent hr) hr) Health Care Providers....................... Baseline Survey for Providers. 23 1 30/60 12 Followup Survey for Providers 23 2 30/60 23 Patients.................................... Screening Script for Patients. 3,333 1 5/60 278 Enrollment Form............... 2,667 1 5/60 222 Baseline Survey for Patients.. 867 1 15/60 217 Followup Survey for Patients. 624 1 10/60 104 Clinic Coordinators......................... Baseline Survey for Clinic 6 1 2 12 Coordinators. Followup Survey for Clinic 6 11 1 66 Coordinators.

Total................................... .............................. ................. ................. ................. 934 [[Page 12451]]

Dated: February 28, 2008.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E84492 Filed 3608; 8:45 am]
BILLING CODE 416318P